Xenetic Biosciences Inc Stock Other OTC
Equities
US9840151073
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
03-21 | Xenetic Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
03-18 | CLS Therapeutics Discloses its Views on Xenetic Biosciences | CI |
Sales 2024 * | 2.13M 2.68M 3.66M | Sales 2025 * | 1.42M 1.78M 2.44M | Capitalization | 5.06M 6.35M 8.68M |
---|---|---|---|---|---|
Net income 2024 * | -4M -5.02M -6.86M | Net income 2025 * | -8M -10.05M -13.72M | EV / Sales 2024 * | 2.37 x |
Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 3.56 x |
P/E ratio 2024 * |
-1.19
x | P/E ratio 2025 * |
-4.99
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 80.81% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 58 | 16-07-10 | |
James F. Parslow
DFI | Director of Finance/CFO | 59 | 17-04-02 |
Curtis Lockshin
CTO | Chief Tech/Sci/R&D Officer | 64 | 14-02-28 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 58 | 16-07-10 | |
Moshe Mizrahy
BRD | Director/Board Member | 71 | - |
Adam Logal
CHM | Chairman | 46 | 17-08-13 |
1st Jan change | Capi. | |
---|---|---|
-2.57% | 103B | |
+1.62% | 95.28B | |
+1.46% | 22.15B | |
-15.51% | 21.02B | |
-8.58% | 18.15B | |
-38.74% | 16.73B | |
-12.74% | 16.05B | |
+5.33% | 13.68B | |
+34.15% | 12.17B |